PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using our proprietary nanoparticle technology platform and other complementary formulation and drug delivery technologies.
Pioneer Surgical Technology is a leading innovator in the design and manufacture of spinal and orthopaedic implants and instruments. The company's proprietary nanocrystalline hydroxyapatite technology - NanOss™ Bone Void Filler - is the first ever nanotechnology medical device to receive clearance by the US Food and Drug Administration (FDA). NanOss™ is an innovative structural biomaterial that is highly osteoconductive and remodels over time into human bone with applications in the sports medicine, trauma, spine and general orthopaedics markets.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
Vascular Magnetics, Inc. is magnetically targeting drug-loaded biodegradable nanoparticles to develop Vascular Magnetic Intervention (VMI), a novel therapy for peripheral artery disease (PAD). PAD is a common chronic condition characterized by obstruction (stenosis) of the arteries in the legs.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.